• Tuesday, July 24th 2018 at 15:00 - 16:00 UK (Other timezones)
  • General participation info   |   Participate online   |   + Phone in United States (Toll Free): 1 877 309 2073 United States: +1 (571) 317-3129 Australia (Toll Free): 1 800 193 385 Australia: +61 2 8355 1020 Austria (Toll Free): 0 800 202148 Belgium (Toll Free): 0 800 78884 Canada (Toll Free): 1 888 455 1389 Denmark (Toll Free): 8090 1924 France (Toll Free): 0 805 541 047 Germany (Toll Free): 0 800 184 4222 Greece (Toll Free): 00 800 4414 3838 Hungary (Toll Free): (06) 80 986 255 Iceland (Toll Free): 800 9869 Ireland (Toll Free): 1 800 946 538 Israel (Toll Free): 1 809 454 830 Italy (Toll Free): 800 793887 Japan (Toll Free): 0 120 663 800 Luxembourg (Toll Free): 800 22104 Netherlands (Toll Free): 0 800 020 0182 New Zealand (Toll Free): 0 800 47 0011 Norway (Toll Free): 800 69 046 Poland (Toll Free): 00 800 1213979 Portugal (Toll Free): 800 819 575 Spain (Toll Free): 800 900 582 Sweden (Toll Free): 0 200 330 905 Switzerland (Toll Free): 0 800 740 393 United Kingdom (Toll Free): 0 800 169 0432 Access Code: 731-636-357

Although depression and anxiety are prevalent and crippling diseases, we lack quantifiable, clinically-actionable targets that are deeply rooted in biology, as is the case for disabling diseases in other areas of medicine. Large-scale studies and meta-analyses of human functional brain imaging have identified at least six macro-scale circuits and that are implicated in self-generated thought, detection of salience, processing of positive and negative emotions, attentional vigilance and cognitive control. Major barriers to utilizing knowledge of these circuits for depression and anxiety include the lack of a standardized protocols for quantifying their function and dysfunction in a reproducible manner, the fragmentation of knowledge due to the focus on dysfunction in one circuit at a time or in a small subset, and the resulting lack of a model for quantifying how brain circuits dysfunctions are expressed in symptoms, behaviors, real world functions and treatment outcomes. A through line in addressing these barriers is the need to quantify rather than smear the heterogeneity in the presentation of depression and anxiety.

In this talk, I demonstrate a new system for deriving clinic-ready metrics that quantify variations in the extent of brain circuit dysfunction in each individual patient with depression and anxiety. This system is anchored in a theoretical model hypothesizing that distinct dysfunctions in brain circuits underlie particular subtypes of depression and anxiety, and that these subtypes cut across our existing broad diagnostic categories. To develop and test this new system we analyzed train, test and generalizability samples of patients with clinically significant symptoms of depression and anxiety. Anchored in a theoretically motivated taxonomy, regression modelling was used to test whether specific circuit dysfunctions predict specific profiles of symptoms, behavior and function. Each regression model was compared against the null distribution of t-scores derived by 10,000 permutations. In the exploratory phase, lasso-penalized regression models were used to explore the more complex structure of how the multiple circuits may combine and interact to predict more nuanced combinations of symptoms, behavior and function.

To advance the actionable significance of our system I include clinical illustrations of how circuit dysfunction targets inform response to different forms of intervention, both pharmacological and non-pharmacological.







Leanne Williams, MD PhD
Professor of Psychiatry and Behavioral Sciences
Department of Psychiatry
Major Laboratories and Clinical & Translational Neurosciences Incubator
Stanford University

Leanne Williams – Deriving quantitative, clinically-actionable biotypes for depression and anxiety

Leave a Reply